stockportfolio.pro
Stocks / KRYS vs OSCR
KRYS vs OSCR: Which Stock Is the Better Buy?
Krystal Biotech, Inc. and Oscar Health, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
KRYS is the larger company ($9.2B vs $8.5B). On the fundamentals, KRYS earns a higher net margin (52.6% vs -3.8%); KRYS has the stronger return on equity (16.8% vs -45.3%). Both carry 2 potential red flags in the filings. Full numbers below — the stronger figure on each row is in green.
AI verdict — KRYS vs OSCR, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Krystal Biotech, Inc. (KRYS) | Oscar Health, Inc. (OSCR) | |
|---|---|---|
| Market cap | $9.2B | $8.5B |
| Revenue (latest FY) | $389.13M | $11.70B |
| Net income (latest FY) | $204.83M | $-443.15M |
| Revenue growth (5y CAGR) | — | 90.8% |
| Net margin | 52.6% | -3.8% |
| Return on equity | 16.8% | -45.3% |
| P/E ratio | 42.0 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 1 |
| Positive free cash flow | Yes | Yes |
Compare with another company:
See the full KRYS vs OSCR breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open KRYS's full financials → Open OSCR's full financials →More comparisons
Frequently asked questions
Which is bigger, KRYS or OSCR?
Krystal Biotech, Inc. is larger by market capitalization — $9.2B versus $8.5B.
Which grows faster, KRYS or OSCR?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.